Effectiveness of 0.05% cyclosporine A eye drops for dry eye disease in patients with thyroid-associated ophthalmopathy: a prospective, parallel-group cohort study.
Yu Zhang, Juan Bao, Cuiyu Wang, Ruiyao Gao, Kai Zhang, Yingxin Chen
{"title":"Effectiveness of 0.05% cyclosporine A eye drops for dry eye disease in patients with thyroid-associated ophthalmopathy: a prospective, parallel-group cohort study.","authors":"Yu Zhang, Juan Bao, Cuiyu Wang, Ruiyao Gao, Kai Zhang, Yingxin Chen","doi":"10.3389/fmed.2026.1951598","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Thyroid-associated ophthalmopathy (TAO) is frequently accompanied by dry eye disease (DED), which can lead to ocular surface damage and decreased visual quality. This study aimed to evaluate the effectiveness of 0.05% cyclosporine A (CsA) eye drops in the treatment of TAO-related DED.</p><p><strong>Methods: </strong>This prospective, parallel-group cohort study included 86 participants diagnosed with TAO-related DED. Participants were divided into either the CsA group (<i>n</i> = 43) or the control group (<i>n</i> = 43). The CsA group received 0.05% CsA eye drops (twice daily), and control group received polyethylene glycol eye drops (four times daily). Ocular parameters were assessed pre-treatment and at 1, 2, and 3 months post-treatment.</p><p><strong>Results: </strong>After 3 months of treatment, the CsA group demonstrated significantly better outcomes than the control group in ocular surface disease index (OSDI) scores, fluorescein tear breakup time (FBUT), and Schirmer I test (SIT) values (all <i>P</i> < 0.05), with between-group differences emerging as early as month 1. Corneal fluorescein staining (CFS) scores also showed significantly greater improvement in the CsA group (<i>P</i> < 0.05). Both groups exhibited comparable improvements in tear meniscus height (TMH) and ocular redness scores over time (<i>P</i> > 0.05). The incidence of adverse events was low in both groups, with all events being mild.</p><p><strong>Conclusion: </strong>0.05% CsA eye drops were associated with improvement in tear film stability, tear secretion, and corneal epithelial integrity in participants with TAO-related DED, and were well tolerated over the 3-month follow-up period.</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"13 ","pages":"1951598"},"PeriodicalIF":3.6000,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13683219/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fmed.2026.1951598","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Thyroid-associated ophthalmopathy (TAO) is frequently accompanied by dry eye disease (DED), which can lead to ocular surface damage and decreased visual quality. This study aimed to evaluate the effectiveness of 0.05% cyclosporine A (CsA) eye drops in the treatment of TAO-related DED.
Methods: This prospective, parallel-group cohort study included 86 participants diagnosed with TAO-related DED. Participants were divided into either the CsA group (n = 43) or the control group (n = 43). The CsA group received 0.05% CsA eye drops (twice daily), and control group received polyethylene glycol eye drops (four times daily). Ocular parameters were assessed pre-treatment and at 1, 2, and 3 months post-treatment.
Results: After 3 months of treatment, the CsA group demonstrated significantly better outcomes than the control group in ocular surface disease index (OSDI) scores, fluorescein tear breakup time (FBUT), and Schirmer I test (SIT) values (all P < 0.05), with between-group differences emerging as early as month 1. Corneal fluorescein staining (CFS) scores also showed significantly greater improvement in the CsA group (P < 0.05). Both groups exhibited comparable improvements in tear meniscus height (TMH) and ocular redness scores over time (P > 0.05). The incidence of adverse events was low in both groups, with all events being mild.
Conclusion: 0.05% CsA eye drops were associated with improvement in tear film stability, tear secretion, and corneal epithelial integrity in participants with TAO-related DED, and were well tolerated over the 3-month follow-up period.
期刊介绍：
Frontiers in Medicine publishes rigorously peer-reviewed research linking basic research to clinical practice and patient care, as well as translating scientific advances into new therapies and diagnostic tools. Led by an outstanding Editorial Board of international experts, this multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide.
In addition to papers that provide a link between basic research and clinical practice, a particular emphasis is given to studies that are directly relevant to patient care. In this spirit, the journal publishes the latest research results and medical knowledge that facilitate the translation of scientific advances into new therapies or diagnostic tools. The full listing of the Specialty Sections represented by Frontiers in Medicine is as listed below. As well as the established medical disciplines, Frontiers in Medicine is launching new sections that together will facilitate
- the use of patient-reported outcomes under real world conditions
- the exploitation of big data and the use of novel information and communication tools in the assessment of new medicines
- the scientific bases for guidelines and decisions from regulatory authorities
- access to medicinal products and medical devices worldwide
- addressing the grand health challenges around the world
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
